within Pharmacolibrary.Drugs.ATC.M;

model M01AE18
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.95,
    Cl             = 0.0025,
    adminDuration  = 600,
    adminMass      = 0.75,
    adminCount     = 1,
    Vd             = 0.01,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.0028333333333333335,
    Tlag           = 10.200000000000001
  );

  annotation(Documentation(
    info ="<html><body><p>Naproxcinod is a nitric oxide-donating prodrug of naproxen, developed as an anti-inflammatory and analgesic agent for the treatment of osteoarthritis and other musculoskeletal disorders. It was investigated as a potentially safer NSAID, aiming to reduce gastrointestinal and cardiovascular side effects. As of now, naproxcinod is not approved for use in any major regulatory jurisdiction and remains an investigational compound.</p><h4>Pharmacokinetics</h4><p>No published human pharmacokinetic models are available; parameters provided below are coarse estimates based on analogies to naproxen and existing public reports on naproxcinod in healthy adult subjects after oral administration.</p><h4>References</h4><ol><li><p>Fagerholm, U, et al., &amp; Hoogstraate, J (2005). Pre-clinical pharmacokinetics of the cyclooxygenase-inhibiting nitric oxide donor (CINOD) AZD3582. <i>The Journal of pharmacy and pharmacology</i> 57(5) 587–597. DOI:<a href=&quot;https://doi.org/10.1211/0022357056028&quot;>10.1211/0022357056028</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/15901348/&quot;>https://pubmed.ncbi.nlm.nih.gov/15901348</a></p></li><li><p>Gund, M, et al., &amp; Satyam, A (2014). Gastric-sparing nitric oxide-releasable &#x27;true&#x27; prodrugs of aspirin and naproxen. <i>Bioorganic &amp; medicinal chemistry letters</i> 24(24) 5587–5592. DOI:<a href=&quot;https://doi.org/10.1016/j.bmcl.2014.10.096&quot;>10.1016/j.bmcl.2014.10.096</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/25466180/&quot;>https://pubmed.ncbi.nlm.nih.gov/25466180</a></p></li><li><p>Hawkey, CJ, et al., &amp; Bjarnason, IT (2003). Gastrointestinal safety of AZD3582, a cyclooxygenase inhibiting nitric oxide donator: proof of concept study in humans. <i>Gut</i> 52(11) 1537–1542. DOI:<a href=&quot;https://doi.org/10.1136/gut.52.11.1537&quot;>10.1136/gut.52.11.1537</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/14570719/&quot;>https://pubmed.ncbi.nlm.nih.gov/14570719</a></p></li></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>"
  ));
end M01AE18;
